Innoviva Inc

Innoviva announced that its wholly owned subsidiary Nortiva Bio has launched as a clinical-stage biopharmaceutical company focused on developing long-acting oral medicines using the proprietary LYNX drug delivery platform. Innoviva acquired the LYNX platform from Lyndra Therapeutics in 2025, and it is designed to transform daily pills into single-dose therapies lasting up to a month across multiple therapeutic areas. The platform is built on foundational science from the labs of Robert Langer and Gio Traverso at MIT and has undergone years of clinical validation, including a successful Phase 3 study.

Innoviva has launched Nortiva Bio, a clinical-stage biopharmaceutical company focused on developing long-acting oral therapies using its proprietary LYNX drug delivery platform. The technology is designed to convert traditional daily oral medicines into extended-release treatments with potential dosing intervals of up to one month. Nortiva Bio operates as a wholly owned subsidiary of Innoviva following the acquisition of the LYNX platform from Lyndra Therapeutics in 2025. Separately, Innoviva Specialty Therapeutics, another subsidiary, announced an exclusive distribution and licensing agreement with Dr. Reddy's Laboratories for XACDURO in selected international markets, covering South and Central America, the Caribbean, Russia, and Commonwealth of Independent States countries. Under the deal, Dr. Reddy's will handle development, regulatory processes, and commercialization, while Innoviva Specialty Therapeutics retains rights outside the licensed regions and is eligible for upfront payments, milestone payments, and royalties.

Innoviva Specialty Therapeutics has entered an exclusive licensing and distribution agreement with Dr. Reddy’s Laboratories to bring XACDURO to South and Central America, the Caribbean, Russia, and the CIS region. The partnership targets carbapenem-resistant Acinetobacter infections, which exceed 70% in these areas. Dr. Reddy’s will handle development, regulatory approval, and commercialization within the territories, while Innoviva retains rights elsewhere and will receive an upfront payment, milestone payments, and tiered royalties on future net sales. XACDURO is FDA-approved for hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter, a pathogen deemed a critical threat.